Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
CONTEXT: It has been suggested that the need for concurrent placebo control groups in new schizophrenia studies might be minimized by making comparisons with external placebo. This strategy requires an assumption of constancy, that the novel medication will perform the same way in a study with only active controls as it would have in a placebo-controlled trial. OBJECTIVE: To test this constancy assumption in active- and low dose-controlled trials vs placebo-controlled trials of atypical antipsychotic medications. DATA SOURCES: A comprehensive search of bibliographic databases, conference proceedings, and Food and Drug Administration databases through November 24, 2003. STUDY SELECTION: English-language, randomized, double-blind clinical trials of newer atypical antipsychotic medications in otherwise unselected acutely ill adults with schizophrenia or schizoaffective disorder that reported baseline and intent-to-treat end point change values for the Brief Psychiatric Rating Scale. DATA EXTRACTION: Study number, sample size, reported dosage for each arm, trial duration, percentage of men, average age, trial arm treatment completion rate, baseline and within-arm end point change in the Brief Psychiatric Rating Scale, method of scoring the Brief Psychiatric Rating Scale, and date of publication were extracted from each study independently by 2 of us (S.W.W. and C.B.B.) each. DATA SYNTHESIS: There were 32 studies comprising 66 risperidone, olanzapine, quetiapine, and ziprasidone arms including 7264 patients. Random-effects analysis revealed that in atypical antipsychotic medication arms, the degree of improvement was nearly double in active-controlled trials than that seen with the same drugs and dosages in placebo-controlled studies. An effect of design was also observed in low dose-controlled studies vs placebo-controlled studies in ineffective and intermediate antipsychotic medication dose ranges. CONCLUSIONS: The observed control group bias indicates that the constancy assumption does not hold in recent antipsychotic medication trials. These results suggest that caution is indicated when considering active- or low dose-controlled studies requiring comparisons with external placebo as alternatives to placebo-controlled trials for establishing efficacy of new medications for schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kraemer, H. C., Stice, E., Kazdin, A., Offord, D., & Kupfer, D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.848 · Cited by 1,712
Interpersonal expectancy effects: the first 345 studies
Rosenthal, R., & Rubin, D. B. (1978) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00075506 · Cited by 1,158
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“Year of publication influenced response rate in both active arms and placebo arms in placebo-controlled antidepressant medication trials published between 1981 and 2000.(111) Some evidence from schizophrenia studies suggests a reduction in response rates in conventional antipsychotic medication arms between the 1960s…”
BackgroundTrials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032 · cited 1×
“Recently, a second, related approach has been developed that seeks to define the equivalence or noninferiority margin using external data from trials that compared the standard with placebo.(30-33) Apart from uncertainties in determining how to appropriately select external placebo data,(25,26,34-36) which will not be…”
Temple, R., & Ellenberg, S. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00014 · Cited by 871
Randomized versus historical controls for clinical trials
Sacks, H., Chalmers, T. C., & Smith, H. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90815-4 · Cited by 834
Ellenberg, S. S., & Temple, R. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00015 · Cited by 331
Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy
Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208
Cited by
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“…et al., 1999), unbalanced randomization may increase the overall placebo response in RCTs, as shown in trials on depression (Papakostas and Fava, 2009; Sinyor et al., 2010; Mancini et al., 2014), schizophrenia (Woods et al., 2005; Mallinckrodt et al., 2010), and psychosis (Agid et al., 2013).”
BackgroundResultChildhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Placebo effects and their determinants in gastrointestinal disorders
Elsenbruch, S., & Enck, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.117 · Cited by 173
Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004824 · Cited by 173
“[49] showed that, in schizophrenia controlled-trials, improvement was larger in trials having no placebo arm; and Trivedi et al.”
Background
Metadata
- Authors
- Woods, S. W., Gueorguieva, R. V., Baker, C. B., & Makuch, R. W.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-01
- Volume
- 62
- Issue
- 9
- Pages
- 961
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2115543503
- Cited by
- 72
- References
- 8
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. https://app.cochat.ai/papers/10.1001/archpsyc.62.9.961
- The paper
- Woods, S. W., Gueorguieva, R. V., Baker, C. B., & Makuch, R. W. (2005). Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.62.9.961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.